Evidence map›Paper›PMID 42353153›Full record

ArticleInternational journal of molecular sciences2026

Serum β-hCG Combined with Traditional Tumor Markers Improves Detection Efficacy and Prognostic Prediction in Cholangiocarcinoma.

Suppakrit Kongsintaweesuk, Thatsanapong Pongking, Keerapach Tunbenjasiri, Pakornkiat Tanasuka, Sittiruk Roytrakul, Sudarat Onsurathum, Chawalit Pairojkul, Kitti Intuyod, Vor Luvira, Somchai Pinlaor and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Suppakrit KongsintaweesukBiomedical Science Program, Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID 0009-0002-6276-5765
Thatsanapong PongkingDepartment of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID 0009-0006-4999-1038
Keerapach TunbenjasiriBiomedical Science Program, Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand.
Pakornkiat TanasukaDepartment of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID 0009-0001-9735-028X
Sittiruk RoytrakulNational Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani 12120, Thailand.ORCID 0000-0003-3696-8390
Sudarat OnsurathumDepartment of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok 65000, Thailand.
Chawalit PairojkulDepartment of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Kitti IntuyodDepartment of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Vor LuviraDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Somchai PinlaorDepartment of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID 0000-0002-8187-7247
David BlairCollege of Science and Engineering, James Cook University, Townsville, QLD 4811, Australia.ORCID 0000-0002-4658-3251
Porntip PinlaorCentre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID 0000-0001-7436-3355

Funding

Khon Kaen University Centre for Research and Development of Medical Diagnostic LaboratoriesNational Institute of Information and Communications Technology ASEAN IVO
6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) in Northeast Thailand is characterized by late diagnosis and poor prognosis, creating a critical need for effective early-detection biomarkers. This study utilized a multi-omics approach to identify novel diagnostic targets and improve CCA screening. Initial serum proteomic and transcriptomic analyses revealed significant upregulation of the luteinizing hormone/choriogonadotropin receptor (LHCGR) in CCA patients, correlating with advanced disease stages. Interaction network analysis subsequently identified its circulating ligand, beta-human chorionic gonadotropin (β-hCG), as a highly translatable clinical target. The protein expression of β-hCG was assessed via immunohistochemistry (IHC) in 100 tissue samples, and serum levels of β-hCG, alongside routine markers (CA19-9, AFP, and CEA), were quantified in a cohort of 405 individuals, including 153 CCA patients. IHC confirmed significantly higher β-hCG expression in tumor tissues compared to adjacent areas (

Indexed as

Bile Duct NeoplasmsBiomarkers, TumorCholangiocarcinomaChorionic Gonadotropin, beta Subunit, HumanAdultAgedalpha-FetoproteinsCA-19-9 AntigenCarcinoembryonic AntigenFemaleHumansMaleMiddle AgedPrognosisalpha-FetoproteinsBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenChorionic Gonadotropin, beta Subunit, Humanbile duct cancerbiomarkerliver cancer

Identifiers

PMID42353153
PMCPMC13299596

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.